panitumumab
Sign in to saveAlso known as ABX-EGF, E7.6.3
Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).
Key facts
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 458269645
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- Epidermal growth factor receptor (EGFR)
- Drug.tradename
- Vectibix
- Drug.MedlinePlus
- a607066
- Drug.licence_EU
- yes
- Drug.DailyMedID
- Panitumumab
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- FE02
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.elimination_half life
- ~9.4 days (range: 4-11 days)
- Drug.CAS_number
- 339177-26-3
via Wikipedia infobox
Research
2,428 papers- Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.The New England journal of medicine · 2023
- Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.JAMA · 2023
- Panitumumab.Drugs of today (Barcelona, Spain : 1998) · 2006
- Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.The New England journal of medicine · 2013
- Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
via PubMed
~5 min read
Encyclopedic overview
13 sectionsContents
- Medical uses
- Contraindications
- Adverse effects
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- FDA approval
- Research
- Panitumumab vs. cetuximab
- References
- Further reading
- External links
Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).
Panitumumab is manufactured by Amgen and was originally developed by Abgenix Inc.
Excerpted from Wikipedia’s “panitumumab” article, available under the CC BY-SA 4.0 licence.